Dysfunctional sarcomere contractility contributes to muscle weakness in ACTA1-related nemaline myopathy (NEM3).
Dysfunctional sarcomere contractility contributes to muscle weakness in ACTA1-related nemaline myopathy (NEM3).
复制标题
DOI:
10.1002/ana.25144
复制
发表时间:
2018-03
影响因子:
11.2
通讯作者:
Ottenheijm CAC
中科院分区:
文献类型:
--
作者:
Joureau B;de Winter JM;Conijn S;Bogaards SJP;Kovacevic I;Kalganov A;Persson M;Lindqvist J;Stienen GJM;Irving TC;Ma W;Yuen M;Clarke NF;Rassier DE;Malfatti E;Romero NB;Beggs AH;Ottenheijm CAC
Nemaline myopathy (NM) is one of the most common congenital non-dystrophic myopathies and is characterized by muscle weakness, often from birth. Mutations in ACTA1 are a frequent cause of NM (i.e. NEM3). ACTA1 encodes alpha-actin 1, the main constituent of the sarcomeric thin filament. The mechanisms by which mutations in ACTA1 contribute to muscle weakness in NEM3 are incompletely understood. We hypothesized that sarcomeric dysfunction contributes to muscle weakness in NEM3 patients. To test this hypothesis, we performed contractility measurements in individual muscle fibers and myofibrils obtained from muscle biopsies of fourteen NEM3 patients with different ACTA1 mutations. To identify the structural basis for impaired contractility, low angle x-ray diffraction and stimulated emission-depletion microscopy were applied. Our findings reveal that muscle fibers of NEM3 patients display a reduced maximal force generating capacity, which is caused by dysfunctional sarcomere contractility in the majority of patients, as revealed by contractility measurements in myofibrils. Low angle x-ray diffraction and stimulated emission-depletion microscopy indicate that dysfunctional sarcomere contractility in NEM3 patients involves a lower number of myosin heads binding to actin during muscle activation. This lower number is not the result of reduced thin filament length. Interestingly, the calcium sensitivity of force is unaffected in some patients, but decreased in others. Thus, dysfunctional sarcomere contractility is an important contributor to muscle weakness in the majority of NEM3 patients, information which is crucial for patient stratification in future clinical trials.
登录
查看更多内容
影响因子:
12.7
作者:
Lindqvist, Johan;Penisson-Besnier, Isabelle;Ochala, Julien
通讯作者:
Ochala, Julien
影响因子:
4
作者:
de Winter JM;Buck D;Hidalgo C;Jasper JR;Malik FI;Clarke NF;Stienen GJ;Lawlor MW;Beggs AH;Ottenheijm CA;Granzier H
通讯作者:
Granzier H
影响因子:
2.8
作者:
Hutchinson, DO;Charlton, A;North, KN
通讯作者:
North, KN
影响因子:
11.2
作者:
Lindqvist J;Levy Y;Pati-Alam A;Hardeman EC;Gregorevic P;Ochala J
通讯作者:
Ochala J
DOI:
10.1097/nen.0b013e318293b1cc
发表时间:
2013-06-01
影响因子:
3.2
作者:
Lindqvist, Johan;Cheng, Arthur J.;Ochala, Julien
通讯作者:
Ochala, Julien